VALERIO THERAPEUTICS

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Phase 1

Recruiting

Conditions: Breast Cancer
Prostate Cancer
Advanced or Metastatic Solid Tumors
Recurrent Ovarian Cancer

Interventions: Drug: VIO-01

First Posted Date: 2024-02-14

Last Posted Date: 2024-06-06

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 165

Registration Number: NCT06257758

Locations: 🇺🇸
Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸
Stephenson Cancer Center - University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
Next Oncology, San Antonio, Texas, United States

Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer
Recurrent Epithelial Ovarian Cancer
Breast Cancer

Interventions: Drug: AsiDNA
Drug: Olaparib

First Posted Date: 2023-01-26

Last Posted Date: 2023-03-31

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 115

Registration Number: NCT05700669

Locations: 🇺🇸
Next Oncology, San Antonio, Texas, United States

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: AsiDNA

First Posted Date: 2018-07-06

Last Posted Date: 2022-03-24

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 33

Registration Number: NCT03579628

Locations: 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪
Grand Hôpital de Charleroi, Charleroi, Belgium
🇫🇷
Centre Leon Berard, Lyon, France

and more 2 locations

Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Catapres 100μg
Drug: Clonidine MBT 50µg
Drug: Clonidine MBT 100µg

First Posted Date: 2015-09-14

Last Posted Date: 2016-04-18

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 36

Registration Number: NCT02548806

Locations: 🇬🇧
Simbec Research Limited, Merthyr Tydfil, United Kingdom

Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Biological: naked DNA coding for protein AMEP

First Posted Date: 2013-01-09

Last Posted Date: 2015-09-11

Lead Sponsor: Valerio Therapeutics

Registration Number: NCT01764009

Locations: 🇸🇮
Institute of Oncology Ljubljana, Ljubljana, Slovenia
🇫🇷
CHU Nancy Hôpital Brabois, Vandoeuvre Les Nancy, France
🇫🇷
Gustave Roussy Institute,, Kremlin Bicetre, France

and more 1 locations

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Doxorubicin 20 mg/m2
Drug: Doxorubicin 30 mg/m2
Drug: Best Standard of Care

First Posted Date: 2012-08-02

Last Posted Date: 2021-06-02

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 397

Registration Number: NCT01655693

Locations: 🇧🇪
CHU Brugmann, Brussels, Belgium
🇧🇪
CHU Sart Tilman, Liège, Belgium
🇪🇬
Medical Oncology department /Ain Shams University Hospitals, Cairo, Egypt

and more 66 locations

Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis

Phase 2

Completed

Conditions: Oral Mucositis

Interventions: Drug: Clonidine Lauriad® 100µg
Drug: Placebo Lauriad®
Drug: Clonidine Lauriad® 50µg

First Posted Date: 2011-06-30

Last Posted Date: 2017-11-28

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 183

Registration Number: NCT01385748

Locations: 🇺🇸
Carolinas Medical Center- Carolinas Health Care System, Charlotte, North Carolina, United States
🇫🇷
Clinique Pasteur, Evreux, France
🇺🇸
21st Century Oncology of Arizona, Sun City, Arizona, United States

and more 47 locations

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Biological: naked DNA coding for protein AMEP

First Posted Date: 2010-01-11

Last Posted Date: 2015-09-11

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 5

Registration Number: NCT01045915

Locations: 🇫🇷
Gustave Roussy Institute, Kremlin Bicetre, France
🇸🇮
Institute of Oncology Ljubljana, Ljubljana, Slovenia
🇩🇰
Copenhagen University Hospital Herlev, Herlev, Denmark

A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

Phase 1

Completed

Conditions: Dose Escalation: Solid Tumors
MTD: Soft Tissue Sarcomas

Interventions: Drug: PXD101
Drug: Doxorubicin

First Posted Date: 2009-04-09

Last Posted Date: 2015-07-28

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 41

Registration Number: NCT00878800

Locations: 🇬🇧
The Royal Marsden NHS Trust, Cancer Research, Surrey, United Kingdom
🇩🇰
Herlev Hospital, Department of Oncology, Herlev, Denmark
🇩🇰
Århus Hospital, Department of Oncology, Århus, Denmark

Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: PXD101
Drug: idarubicin

First Posted Date: 2009-04-09

Last Posted Date: 2015-07-28

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 41

Registration Number: NCT00878722

Locations: 🇫🇷
Hôpital St. Louis, Paris, France
🇩🇪
Uniklinik Homburg, Homburg, Germany
🇩🇪
Uni Hospital Marburg, Marburg, Germany

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy